New Therapeutics to Treat Castrate-Resistant Prostate Cancer

Table 1

Treatments that have demonstrated OS benefit in Phase III trials with CRPC patients.

Treatment	Trial name and NCT identifier	Patient size	Indication	Control arm	Median OS in months (drug versus control)
Cabazitaxel/prednisone	TROPIC (NCT417079); [6]	755	Post-docetaxel	Mitoxantrone and prednisone	15.1 versus 12.7
Abiraterone/prednisone	COU-AA-301 (NCT638690); [7]	1195	Post-docetaxel	Placebo and prednisone	14.8 versus 10.9
Enzalutamide	AFFIRM (NCT974311); [8]	1199	Post-docetaxel	Placebo	18.4 versus 13.6
Sipuleucel-T	IMPACT (NCT65442); [9]	512	Post-docetaxel	PBMCs control	25.8 versus 21.7
Alpharadin	ALSYMPCA (NCT699751); [10]	922	Bone metastasis	Placebo and best standard care	14.0 versus 11.2